Mariner
AUPH icon

Mariner’s Aurinia Pharmaceuticals AUPH Stock Holding History

Mariner’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$807K Buy
54,435
+33,898
+165% +$495K ﹤0.01% 2121
2025
Q4 		$327K Buy
20,537
+6,364
+45% +$90.2K ﹤0.01% 2767
2025
Q3 		$157K Buy
+14,173
New +$155K ﹤0.01% 3258

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mariner's AUPH Position: Q1 2026 in Review

Mariner increased its Aurinia Pharmaceuticals (AUPH) stake by 165% in Q1 2026, buying an estimated $495K and bringing the position to 54,435 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

Mariner first reported a position in AUPH in Q3 2025 and has held it in 3 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Mariner held 54,435 shares of Aurinia Pharmaceuticals worth $807K as of Q1 2026.
  • Mariner bought 33,898 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $495K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2121 holding.
  • Mariner first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.